Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
    • Philanthropic Consulting
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data

BY Benzinga
— 8:49 AM ET 06/15/2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

Pfizer Halts Enrollment In Paxlovid COVID-19 Trial In Standard-Risk Population

Pfizer Inc NYSE:PFE shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid in patients at standard risk of developing severe COVID-19. 

An updated analysis from 1,153 patients showed a non-significant 51% relative risk reduction. 

Pfizer said it would halt enrollment in the EPIC-SR trial in standard-risk patients as the study revealed the treatment was ineffective in reducing symptoms in that group.

FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report

Moderna Inc's NASDAQ:MRNA COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17.

Children ages 6 to 11 would receive smaller 50 microgram shots, while teens ages 12 to 17 would receive the same dosage as adults at 100 micrograms.

MorphoSys, Enters Equity Participation and License Agreements With HIBio

MorphoSys AG NASDAQ:MOR and Human Immunology Biosciences, Inc (HIBio) established an equity participation agreement and license agreements.

As per the agreements, HIBio obtains exclusive rights to develop and commercialize felzartamab and MOR210 across all indications worldwide, except Greater China for felzartamab and Greater China and South Korea for MOR210.

MorphoSys will receive a 15% equity stake in HIBio, and up to $1 billion in milestone payments across programs, plus double-digit royalties on net sales. MorphoSys receives an upfront payment of $15 million for MOR210.

MOR shares are up 9.65% at $5.00 during the premarket session.

180 Life Sciences Stock Plunges On UK, FDA Feedback On Early-Stage Dupuytren's Disease Therapy

The U.K. agency says that 180 Life Sciences Corp's NASDAQ:ATNF adalimumab study's primary endpoint of nodule hardness and the secondary endpoint of nodule size would require evidence to validate them as clinically meaningful surrogate endpoints.

The FDA indicated that the proposed outcome measures of nodule hardness and nodule size are not clinical outcomes.

Shares are down 38.7% at 82 cents during the premarket session.

Omega Files To Start Human Trial For Lead Candidate In Liver Cancer

Omega Therapeutics Inc NASDAQ:OMGA has submitted an Investigational New Drug Application to the FDA for its lead product candidate, OTX-2002, for hepatocellular carcinoma.

The company plans to initiate a Phase 1 clinical trial in the U.S. to evaluate OTX-2002, following FDA clearance.

Also See: Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Kymera Starts Dosing In Early-Stage Solid Tumor, Blood Cancer Trials

Kymera Therapeutics Inc NASDAQ:KYMR has recently dosed the first patients in separate Phase 1 trials evaluating KT-333 and KT-413. 

The KT-333 trial includes patients with relapsed/refractory liquid and solid tumors, including T-cell lymphomas and leukemia.

The KT-413 study is enrolling patients with relapsed/refractory B cell lymphomas, including MYD88-mutant diffuse large B cell lymphoma.

Clinical Readouts/Presentations

Akero Therapeutics Inc NASDAQ:AKRO: Present at Keystone Symposium on Efruxifermin as a therapy for nonalcoholic steatohepatitis.

Offerings

VectivBio Holding AG NASDAQ:VECT has priced a public offering of 5.715 million shares at $5.25 per share for aggregate gross proceeds of approximately $30 million.

Day One Biopharmaceuticals NASDAQ:DAWN has priced its upsized public offering of 10 million shares at $15.00 per share, with gross proceeds of $150 million versus an earlier announcement of $125 million.

On The Radar

FDA Meeting

The outside experts will meet to consider the Moderna Inc NASDAQ:MRNA COVID-19 shot for children under six years and Pfizer Inc NYSE:PFE and BioNTech SE's NASDAQ:BNTX COVID vaccine for children under 5 - and in both cases as young as six months.

Stock Split

Calithera Biosciences Inc NASDAQ:CALA filed to effect a 1-for-20 reverse stock split, effective as of 5:00 p.m. ET Tuesday.

More BNTX News

  • Morning Brief: Top Financial Stories Dominating on Wednesday, June 15
    Benzinga - 8:17 AM ET 06/15/2022
  • FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report
    Benzinga - 7:19 AM ET 06/15/2022
  • EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters
    Benzinga - 1:28 PM ET 06/14/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close